Logo image
Back
Abstract 020: CEREGLIDE 71 Aspiration Catheter for Stroke Thrombectomy An Initial Multicenter US Experience
Abstract   Open access   Peer reviewed

Abstract 020: CEREGLIDE 71 Aspiration Catheter for Stroke Thrombectomy An Initial Multicenter US Experience

S Majidi, R Grandhi, E Samaniego, C Kilburg, K Budohoski, P Reddi, I Moini-Naghani, A Jain and F Al-Mufti
Stroke: vascular and interventional neurology, Vol.4(S1)
11/01/2024
DOI: 10.1161/SVIN.04.suppl_1.020
PMCID: PMC12773842
url
https://doi.org/10.1161/SVIN.04.suppl_1.020View
Published (Version of record) Open Access

Abstract

CEREGLIDE 71 Aspiration Catheter for Stroke Thrombectomy: An Initial Multicenter US ExperienceIntroduction/PurposeLarge bore aspiration catheters have revolutionized stroke thrombectomy in recent years. The aim of this study was to report for the first time the safety and technical success of using CEREGLIDE 71 (ID 0.071”) (CERENOVUS, Irvine, CA) in routine clinical practice in patients with proximal large vessel occlusions (LVO).Patients and MethodsThis is a retrospective multicenter study which combines consecutive patients from 4 comprehensive stroke centers in the United States who underwent endovascular thrombectomy for proximal LVO with the CEREGLIDE 71 aspiration catheter used in at least one pass, either for direct aspiration or in combination with a stent retriever. Technical and safety outcomes are summarized in Table 1. Independent image assessment is ongoing and has been completed for over half of the subjects.ResultsA total of 61 consecutive patients (mean age 65.6±16.30; 54.1% female, 31.1% self‐reported non‐White) treated between October 2023 and June 2024 were included. The most frequent occlusion site was M1 (72.9%), followed by ICA and M2. Additionally, one patient had occlusions affecting both the anterior (ICA,M1) and posterior circulations (Basilar artery). Most cases 82% (50/61) involved at least one challenging anatomical feature (see Table 1). CEREGLIDE 71 was used in first pass in 59/61 subjects and achieved mTICI2c‐3 in 36.1% (22/61) cases, with direct aspiration technique in 66.1% (39/59) cases. Final mTICI≥2b was 95.1%, with a mean number 2.3±1.62 passes and mean procedure to recanalization time of 40.7±28.16 minutes (median of 34.0 minutes). The target occlusion was reached in 99.1 % (112/113) of passes performed with CEREGLIDE 71. Of those, 80 passes were targeting the M1 and 98.8% (79/80) were successfully reached. There were no device related adverse events and no device damage (e.g. kinking, tip damage, other), with one case of procedure‐related vessel dissection and two cases of sICH (Table 1).ConclusionIn this initial real‐world multicenter experience, CEREGLIDE 71 demonstrated good technical success in terms of successfully reaching the M1 location, first pass reperfusion, and device durability, with low procedural complications.
 Stroke Catheters

Details

Metrics

39 Record Views
Logo image